Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
33327 | 94 | 34.6 | 87% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
876 | 10798 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//ABCG2 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | L1210 CELL LINE | Author keyword | 6 | 71% | 5% | 5 |
2 | TCRP1 | Author keyword | 6 | 100% | 4% | 4 |
3 | MOL PHYSIOL GENET | Address | 4 | 10% | 41% | 39 |
4 | EXCELLENCE SLOVAK DEV AGCY BIOMEMBRANES | Address | 4 | 75% | 3% | 3 |
5 | P GP MEDIATED MDR | Author keyword | 3 | 100% | 3% | 3 |
6 | L1210 CELLS | Author keyword | 3 | 22% | 12% | 11 |
7 | SLOVAK DEV AGCY BIOMEMBRANES2008 | Address | 2 | 67% | 2% | 2 |
8 | CELL SURFACE SACCHARIDES | Author keyword | 1 | 100% | 2% | 2 |
9 | L1210 LEUKEMIC CELL LINES | Author keyword | 1 | 100% | 2% | 2 |
10 | MOUSE LEUKAEMIA CELLS L1210 | Author keyword | 1 | 100% | 2% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | L1210 CELL LINE | 6 | 71% | 5% | 5 | Search L1210+CELL+LINE | Search L1210+CELL+LINE |
2 | TCRP1 | 6 | 100% | 4% | 4 | Search TCRP1 | Search TCRP1 |
3 | P GP MEDIATED MDR | 3 | 100% | 3% | 3 | Search P+GP+MEDIATED+MDR | Search P+GP+MEDIATED+MDR |
4 | L1210 CELLS | 3 | 22% | 12% | 11 | Search L1210+CELLS | Search L1210+CELLS |
5 | CELL SURFACE SACCHARIDES | 1 | 100% | 2% | 2 | Search CELL+SURFACE+SACCHARIDES | Search CELL+SURFACE+SACCHARIDES |
6 | L1210 LEUKEMIC CELL LINES | 1 | 100% | 2% | 2 | Search L1210+LEUKEMIC+CELL+LINES | Search L1210+LEUKEMIC+CELL+LINES |
7 | MOUSE LEUKAEMIA CELLS L1210 | 1 | 100% | 2% | 2 | Search MOUSE+LEUKAEMIA+CELLS+L1210 | Search MOUSE+LEUKAEMIA+CELLS+L1210 |
8 | PENTOXIFYLLINE ANALOGUES | 1 | 100% | 2% | 2 | Search PENTOXIFYLLINE+ANALOGUES | Search PENTOXIFYLLINE+ANALOGUES |
9 | DDP RESISTANCE | 1 | 50% | 1% | 1 | Search DDP+RESISTANCE | Search DDP+RESISTANCE |
10 | LYCOPERSICUM ESCULENTUM AGGLUTININ | 1 | 50% | 1% | 1 | Search LYCOPERSICUM+ESCULENTUM+AGGLUTININ | Search LYCOPERSICUM+ESCULENTUM+AGGLUTININ |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MEDIATED VINCRISTINE RESISTANCE | 15 | 82% | 10% | 9 |
2 | L1210 VCR CELLS | 14 | 100% | 7% | 7 |
3 | MOUSE LEUKEMIC CELLS | 2 | 50% | 3% | 3 |
4 | CIS DICHLORODIAMMINE PLATINUMII | 1 | 50% | 1% | 1 |
5 | MOUSE LEUKEMIA CELLS | 0 | 11% | 4% | 4 |
6 | P GLYCOPROTEIN OVEREXPRESSION | 0 | 33% | 1% | 1 |
7 | PZR | 0 | 33% | 1% | 1 |
8 | BLEOMYCIN SENSITIVITY | 0 | 17% | 1% | 1 |
9 | ABC TRANSPORTER TAP | 0 | 14% | 1% | 1 |
10 | ACQUIRED MULTIDRUG RESISTANCE | 0 | 14% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
P-glycoprotein - Implications of metabolism of neoplastic cells and cancer therapy | 2005 | 77 | 150 | 13% |
Drug transporters and their role in multidrug resistance of neoplastic cells | 2001 | 21 | 133 | 5% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MOL PHYSIOL GENET | 4 | 10% | 41% | 39 |
2 | EXCELLENCE SLOVAK DEV AGCY BIOMEMBRANES | 4 | 75% | 3.2% | 3 |
3 | SLOVAK DEV AGCY BIOMEMBRANES2008 | 2 | 67% | 2.1% | 2 |
4 | SEBIC | 1 | 50% | 1.1% | 1 |
5 | SLOVAK DEV AGCY BIOMEMBRANES 2008 | 1 | 50% | 1.1% | 1 |
6 | GREENEBAUM CANC MED | 0 | 33% | 1.1% | 1 |
7 | ICRF MOL PHARMACOL UNIT | 0 | 25% | 1.1% | 1 |
8 | PHYSIOL IMMUNOL ANIM | 0 | 13% | 1.1% | 1 |
9 | ALL IRELAND NCI CANC CONSORTIUM | 0 | 100% | 1.1% | 1 |
10 | EXCELLENCE SLOVAK DEV AGCY | 0 | 100% | 1.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000214098 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//PSC 833 |
2 | 0.0000185308 | SORCIN//TRAP1//HAISHENGSU |
3 | 0.0000093680 | MAJOR VAULT PROTEIN//LUNG RESISTANCE RELATED PROTEIN//VPARP |
4 | 0.0000085846 | ABCG2//BCRP//BREAST CANCER RESISTANCE PROTEIN |
5 | 0.0000083509 | TMEM132A//C FOS SERUM RESPONSE ELEMENT//FAS FASL INTERACTIONS |
6 | 0.0000070967 | MRP1//MULTIDRUG RESISTANCE ASSOCIATED PROTEIN//DUBIN JOHNSON SYNDROME |
7 | 0.0000069947 | BIKDD//MITOCHONDRIAL CYTOCHROME C RELEASE//BAX OVEREXPRESSION |
8 | 0.0000067616 | TAT BH4//MOL CELLULAR SIGNALING//BIOEMERGENCES IBISA |
9 | 0.0000066083 | CISPLATIN RESISTANCE//PLATINUM DNA ADDUCTS//HUMAN OVARIAN CANCER CELL LINE |
10 | 0.0000062495 | PENTOXIFYLLINE//LISOFYLLINE//GUDE |